Ocumension Therapeutics Future Growth
Future criteria checks 5/6
Ocumension Therapeutics is forecast to grow earnings and revenue by 93.7% and 35.2% per annum respectively. EPS is expected to grow by 86.3% per annum. Return on equity is forecast to be 3.8% in 3 years.
Key information
93.7%
Earnings growth rate
86.3%
EPS growth rate
Pharmaceuticals earnings growth | 11.9% |
Revenue growth rate | 35.2% |
Future return on equity | 3.8% |
Analyst coverage | Low |
Last updated | 07 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,307 | 205 | 69 | N/A | 3 |
12/31/2025 | 800 | -3 | 95 | 209 | 3 |
12/31/2024 | 437 | -251 | 218 | 293 | 3 |
12/31/2023 | 246 | -380 | -540 | -178 | N/A |
9/30/2023 | 227 | -399 | -561 | -223 | N/A |
6/30/2023 | 208 | -418 | -582 | -269 | N/A |
3/31/2023 | 184 | -411 | -546 | -235 | N/A |
12/31/2022 | 159 | -403 | -511 | -201 | N/A |
9/30/2022 | 124 | -393 | -615 | -165 | N/A |
6/30/2022 | 90 | -383 | -720 | -129 | N/A |
3/31/2022 | 73 | -322 | -791 | -163 | N/A |
12/31/2021 | 56 | -260 | -862 | -197 | N/A |
9/30/2021 | 44 | -426 | -760 | -232 | N/A |
6/30/2021 | 32 | -593 | -659 | -267 | N/A |
3/31/2021 | 23 | -1,429 | -588 | -240 | N/A |
12/31/2020 | 13 | -2,265 | -517 | -213 | N/A |
9/30/2020 | 8 | -2,540 | -407 | -173 | N/A |
6/30/2020 | 2 | -2,816 | -297 | -133 | N/A |
3/31/2020 | 1 | -2,064 | -203 | -120 | N/A |
12/31/2019 | 0 | -1,312 | -109 | -108 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1477 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: 1477 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 1477 is expected to become profitable in the next 3 years.
Revenue vs Market: 1477's revenue (35.2% per year) is forecast to grow faster than the Hong Kong market (7.9% per year).
High Growth Revenue: 1477's revenue (35.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1477's Return on Equity is forecast to be low in 3 years time (3.8%).